Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SMARCB1-Deficient Malignancies”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Looking for participantsNCT06444880
What this trial is testing

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Who this might be right for
SMARCB1-Deficient MalignanciesEpithelioid SarcomaMedullary Carcinoma
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05407441
What this trial is testing

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Who this might be right for
Atypical Teratoid Rhabdoid TumorINI1 (SMARCB1)-Deficient Primary CNS Malignant TumorsSMARCA4-deficient Primary CNS Malignant Tumors+4 more
Susan Chi, MD 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT05286801
What this trial is testing

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Who this might be right for
Atypical Teratoid/Rhabdoid TumorEpithelioid SarcomaKidney Medullary Carcinoma+15 more
National Cancer Institute (NCI) 86